A Longitudinal Study of Choroidal Changes After Cataract Surgery in Eyes With Diabetic Retinopathy

Sponsor
Ruijin Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04499768
Collaborator
(none)
46
1
31
1.5

Study Details

Study Description

Brief Summary

To determine the influence of phacoemulsification on choroidal vasculature in patients with diabetic retinopathy (DR) undergoing cataract surgery

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    To determine the influence of phacoemulsification on choroidal vasculature in patients with diabetic retinopathy (DR) undergoing cataract surgery through the follow-up of choroidal thickness (CT) and choroidal vascularity index (CVI) using swept-source optical coherence tomography (SS-OCT) system.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    46 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    A Longitudinal Study of Choroidal Changes Assessed With Swept-source Optical Coherence Tomography After Cataract Surgery in Eyes With Diabetic Retinopathy
    Actual Study Start Date :
    Jun 1, 2018
    Actual Primary Completion Date :
    Oct 30, 2019
    Anticipated Study Completion Date :
    Dec 30, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    control

    the age-related cataract patients

    DR group

    the cataract patients with mild/moderate NPDR

    Outcome Measures

    Primary Outcome Measures

    1. CVI at baseline [CVI was assessed at baseline(within 1 week before surgery)]

      choroidal vascularity index(CVI) was defined as the proportion of vascular area to total circumscribed area.

    2. CVI at 1 week postoperatively [CVI was assessed 1 week after surgery.]

      choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area.

    3. CVI at 1 month postoperatively [CVI was assessed 1 month after surgery.]

      choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area.

    4. CVI at 3 months postoperatively [CVI was assessed 3 months after surgery.]

      choroidal vascularity index (CVI)was defined as the proportion of vascular area to total circumscribed area.

    5. CT at baseline [CT was assessed at baseline and 1 week, 1 month, 3 month after surgery.]

      Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.

    6. CT at 1 week postoperatively [CT was assessed at 1 week after surgery.]

      Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.

    7. CT at 1 month postoperatively [CT was assessed at 1 month after surgery.]

      Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.

    8. CT at 3 months postoperatively [CT was assessed at 3 months after surgery.]

      Choroid thickness (CT) was the thickness of the choroidal layer, CT values were obtained with the built-in software of the SS-OCT device.

    9. VD at baseline [VD of the choriocapillaris was assessed at baseline.]

      VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.

    10. VD at 1 week postoperatively [VD of the choriocapillaris was assessed 1 week after surgery.]

      VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.

    11. VD at 1 month postoperatively [VD of the choriocapillaris was assessed 1 month after surgery.]

      VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.

    12. VD at 3 months postoperatively [VD of the choriocapillaris was assessed 3 months after surgery.]

      VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid

    Secondary Outcome Measures

    1. IOP at baseline [IOP was assessed at baseline and 1 week, 1 month, 3 month after surgery.]

      IOP was the value of intraocular pressure.

    2. IOP at 1 week postoperatively [IOP was assessed 1 week after surgery.]

      IOP was the value of intraocular pressure .

    3. IOP at 1 month postoperatively [IOP was assessed 1 month after surgery.]

      IOP was the value of intraocular pressure.

    4. IOP at 3 months postoperatively [IOP was assessed 3 months after surgery.]

      IOP was the value of intraocular pressure .

    5. BCVA at baseline [BCVA was assessed at baseline .]

      BCVA was the best corrected visual acuity.

    6. BCVA at 3 months postoperatively [BCVA was assessed 3 months after surgery.]

      BCVA was the best corrected visual acuity.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 80 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • agedā©¾40years; intraocular pressure (IOP) < 21 mm Hg in both eyes, spherical refractive error<6 diopters spherical equivalent.
    Exclusion Criteria:
    • previous retinal surgery, glaucoma, uveitis, age-related macular degeneration, arterial or vein occlusions, macular hole, or other ocular diseases that could interfere the CT and/or CVI measurement, severe systemic diseases, such as uncontrolled hypertension, obstructive sleep apnea, etc.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ruijin Hospital Shanghai Shanghai China 200025

    Sponsors and Collaborators

    • Ruijin Hospital

    Investigators

    • Study Director: Xi Shen, PhD, Shanghai Jiao Tong University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Xi Shen, chief physician, Ruijin Hospital
    ClinicalTrials.gov Identifier:
    NCT04499768
    Other Study ID Numbers:
    • 2018ZY14
    First Posted:
    Aug 5, 2020
    Last Update Posted:
    Aug 5, 2020
    Last Verified:
    Aug 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Xi Shen, chief physician, Ruijin Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 5, 2020